Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iloprost - Bayer HealthCare Pharmaceuticals

Next Previous
X
Search
Drug Profile

Iloprost - Bayer HealthCare Pharmaceuticals

Alternative Names: BAYQ 6256; Breelib; Ciloprost; E-1030; Endoprost; Ilocit; Iloderm; Ilomedin; Ilomedine; Iloprost inhalation solution; Iloprost power 15 (Ventavis®) - Actelion; Iloprost trometamol; Isoiloprost; SH-401; Ventavis; VR-876 - Vectura; ZK-36375

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Bayer HealthCare Pharmaceuticals
  • Class Alkynes; Anti-ischaemics; Antiplatelets; Peripheral vasodilators; Prostaglandins; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Epoprostenol agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Pulmonary arterial hypertension; Raynaud's disease; Thromboangiitis obliterans
  • Discontinued Pulmonary hypertension

Most Recent Events

  • 01 Jul 2019 Iloprost is not yet available for Pulmonary arterial hypertension in Iceland and Liechtenstein (Inhalation)
  • 29 Sep 2017 Bayer completes a phase I/II trial in Pulmonary-hypertension in Austria, Germany (NCT02032836)
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top